20/20 Biolabs, Inc. — Form 8-K
Filed August 17, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 42/100
What the filing says
20/20 BioLabs reported Q2 2026 revenue of $0.73M (+36.5% YoY), with OneTest cancer screening revenue up 47.1% to $0.7M (95.3% of total). Gross profit surged 86.6% to $0.3M with margin expanding to 41.7% from 30.5%. Cash strengthened to $4.5M (from $1.0M YE2025) via $6.0M Series E preferred issuance; all convertible note debt eliminated via exchange for 583 Series E shares on April 10, 2026. State firefighter programs (Vermont 12-month, Maryland $520K award) expected to generate >$1.0M revenue through 2026.
Why this rating
Strong revenue growth (+37% QoQ) and margin expansion, debt elimination, and cash raise are operationally positive. However, net loss widened to $1.5M (Q2) and $3.7M (H1), company still unprofitable. At $5.8M total assets, $0.73M quarterly revenue is material but early-stage. No regulatory or inflection-point catalyst yet evident—growth is modest in absolute dollars.
See more from August 17, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.